AGEPHA Pharma FZ LLC
$93.7K 510 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OnMark, Inc.
OnMark, Inc. reported $93,720.70 across General Payments, Research, and Ownership to 63 physicians and teaching hospitals across 63 transactions.
- $93.7K Below-median payer
- All-tracks total
- 63 Below-median volume
- Transactions
- 63 Below-median reach
- Recipients
- +$60.3K
- General Payments vs PY2023
OnMark, Inc. reported $93,720.70 across all CMS Open Payments tracks (General + Research + Ownership) to 63 physicians and teaching hospitals in Program Year 2024 - ranking #1201 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $93,720.70, averaging $1.5K per recipient.
OnMark, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer onmark-inc OnMark, Inc.
$93.7K · #1201/1,925 · 0.0% industry · PY2024
- TOT $93.7K
- RANK #1201
- SHARE 0.0%
- TXN 63
- RCP 63
- CAT 3
- GEN $93.7K
- ΔGEN +$60.3K
- TOP1 34.6%
- PY 2024
Volume peers
Nearest volume peer: AGEPHA Pharma FZ LLC ($93.7K)
OnMark, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OnMark, Inc.'s CMS-reported General Payments increased by $60.3K (+180.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ONMARK, INC.PY2023: ONMARK, INC.PY2024: OnMark, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $33,439.98
- PY2024
- $93,720.70
What the Data Shows for OnMark, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For OnMark, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $89.4K across 25 transactions, 95.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
OnMark, Inc. made 3 types of general payments. "Consulting Fee" is the largest category at $89.4K, 95.3% of General Payments.
How OnMark, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $89.4K | 25 | 95.3% |
| Food and Beverage | $2.2K | 32 | 2.4% |
| Travel and Lodging | $2.2K | 6 | 2.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $69,951.41 (74.6%) of $93,720.70 in this company's General Payments records across 17 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OnMark, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
David James Mooney
$32,464.84 across 19 reported transactions
- 2
Mohsen Arani
$20,405.89 across 12 reported transactions
- 3
Jed Hamad Assam
$5,929.80 across 2 reported transactions
- 4
Tirso Mark Lara
$5,655.59 across 2 reported transactions
- 5
Joseph Kannarkatt
$5,495.29 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
OnMark, Inc. ranks #1201 of 1,925 by total payments (bottom 38% by spend) but is notably more concentrated than that alone would suggest -- #770 of 1,838 by HHI (top 42% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- United Imaging Healthcare North America, Inc. : $270.2K total payments, HHI 1892
- ulrich medical USA, Inc. : $199.2K total payments, HHI 1891
- NeuroOne Medical Technologies Corporation : $44.7K total payments, HHI 1889
- Eminent Spine, LLC : $35.3K total payments, HHI 1889
- SiVantage, Inc. : $3.8K total payments, HHI 1887
- Air Techniques, Inc. : $23.7K total payments, HHI 1886
- OnMark, Inc. (this company) : $93.7K total payments, HHI 1884
- Sechrist Industries Inc : $740.50 total payments, HHI 1882
- Reichert, Inc. : $186.8K total payments, HHI 1880
- Canary Medical USA LLC : $754.5K total payments, HHI 1873
- Avyxa Pharma, LLC : $17.2K total payments, HHI 1863
- Amarin Pharma Inc. : $199.3K total payments, HHI 1855
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OnMark, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OnMark, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OnMark, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Seapearl East, Inc
$93.9K 982 recipients
Compare payment profiles
Accriva Diagnostics Inc.
$94.1K 0 recipients
Compare payment profiles
Oasis Medical, Inc.
$94.3K 82 recipients
Compare payment profiles
Banner Life Sciences, LLC
$92.8K 2,044 recipients
Compare payment profiles
Mitsubishi Tanabe Pharma Corporation
$92.7K 45 recipients
Compare payment profiles
Put this to use
OnMark, Inc. ranks #1201 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just OnMark, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.